hrp0097rfc12.1 | Thyroid | ESPE2023

Macro-TSH IgG complex in a case of Congenital Hypothyroidism (CH).

Ippolito Alessia , Vincenzi Gaia , Abbate Marco , Campi Irene , Del Giacco Luisa , Pontillo Marina , Persani Luca , Barera Graziano , Cristina Vigone Maria

We present the case of a five-day female admitted to our Paediatric Unit due to TSH elevation (bTSH 303 mIU/L) on routine neonatal screening for congenital hypothyroidism (CH). The patient was born at 38 weeks’ gestation by c-section presenting with adequate auxological parameters. Her mother suffered from Hashimoto’s disease, already diagnosed before pregnancy, and requiring Levo-thyroxine therapy (L-T4). Blood tests performed at five days of life revealed the pre...

hrp0098rfc12.5 | Thyroid | ESPE2024

Use of the FT3/FT4 ratio as a predictor of relapse in autoimmune hyperthyroidism: retrospective study on a cohort of 80 pediatric patients

Borysewicz-Sańczyk Hanna , Abbate Marco , Vincenzi Gaia , Mora Stefano , Tarantola Giulia , Santagiuliana Cristina , Teresa Petralia Ilenia , Del Giacco Luisa , Barera Graziano , Cristina Vigone Maria

The overall remission rate after 2 years of anti-thyroid drug treatment (ATD) in pediatric patients with autoimmune hyperthyroidism (AI) is 20-30%. The European Thyroid Association (ETA) recommends longer duration of ATD therapy in patients who have low likelihood of remission. Older age, female sex, ethnicity, small goiter, mild biochemical derangement at diagnosis, lower TSH receptor antibodies (TRAb) titer, history of other autoimmune conditions, duration of ATD treatment, ...